Physician profile
Timothy Trainor
NPI 1871555136
$10,795.09
in general payments reported to CMS, 2019-2025
34 companies · $18.16 in 2025
The $18.16 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,544 · 2020: $1,676 · 2021: $2,122 · 2022: $2,089 · 2023: $2,292 · 2024: $1,054 · 2025: $18.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,255 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,255.39 |
| Education | $108.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,361.87 | 2019-2024 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,474.90 | 2019-2024 | Trulance, Xifaxan, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $898.73 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $882.70 | 2019-2024 | Stelara, Simponi Aria, Simponi |
| Pfizer INC. | $576.30 | 2019-2024 | |
| Gilead Sciences, INC. | $555.70 | 2019-2024 | |
| Celgene Corporation | $391.05 | 2022-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $353.07 | 2019-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $299.43 | 2019-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $243.54 | 2019-2024 | Ocaliva |
| Boston Scientific Corporation | $225.01 | 2019-2020 | |
| Lilly USA, LLC | $173.73 | 2023-2024 | Omvoh |
| Nestle Healthcare Nutrition INC. | $144.52 | 2021-2023 | |
| Conmed Corporation | $131.70 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $125.68 | 2024 | Dupixent |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $121.56 | 2019-2022 | |
| Ardelyx, INC. | $111.10 | 2022-2023 | Ibsrela |
| Romark Laboratories, Lc | $103.13 | 2019-2020 | |
| Daiichi Sankyo INC. | $96.21 | 2019-2024 | Injectafer |
| Genzyme Corporation | $87.11 | 2022-2023 | |
| Shionogi INC | $68.06 | 2019 | |
| Ucb, INC. | $58.90 | 2019-2020 | |
| Alfasigma USA, INC. | $48.99 | 2020-2021 | |
| Shire North American Group INC | $39.98 | 2019 | |
| Redhill Biopharma INC. | $37.43 | 2020 | |
| Pharmacosmos Therapeutics INC. | $36.69 | 2021 | |
| Axonics, INC. | $35.13 | 2021 | |
| Ferring Pharmaceuticals INC. | $23.11 | 2019-2020 | |
| Braintree Laboratories, INC. | $21.27 | 2022 | |
| Amgen INC. | $20.42 | 2022 | |
| Celltrion USA INC. | $19.46 | 2024 | Zymfentra |
| Evoke Pharma, INC. | $15.05 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.56 | 2024 | Voquezna |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$20,648.97 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Trainor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.